Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024862 · ClinicalTrials.gov registry record
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
A clinical trial of Metastatic Non Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT07024862 is a study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 100 participants, below the 390-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07024862, a study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
Conditions Studied
Interventions
- BIOLOGICAL nivolumab + ipilimumab
Study Locations (1)
Ohio
- Cardinal Health - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2025-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024862
The ClinicalTrials.gov registry entry for NCT07024862 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 390-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which nivolumab + ipilimumab is the first listed.
NCT07024862 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07024862 about?
NCT07024862 is a clinical study titled "Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy". The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US
What is the current status of trial NCT07024862?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2024-10-24. Estimated completion is 2025-06-30.
What conditions does trial NCT07024862 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT07024862?
The interventions under investigation include: nivolumab + ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07024862?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024862 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RECRUITING · Phase 1
-
MOv19-BBz CAR T Cells in FRa+ Cancers
RECRUITING · Phase 1
-
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.